Business Wire

The LYCRA Company Announces Collaboration With Qore ® to Use QIRA ® for Next Generation Bio-derived LYCRA ® Fiber at Scale

Share

The LYCRA Company,a global leader in developing innovative fiber and technology solutions for the textile and apparel industry, today announced it has entered into an agreement with Qore® to enable the world’s first large-scale commercial production of bio-derived spandex using QIRA®, the next generation 1,4-butanediol (BDO), as one of its main ingredients. This will result in 70% of the LYCRA® fiber content being derived from annually renewable feedstock. This change could potentially reduce the carbon footprint of LYCRA® fiber by up to 44%* versus equivalent product made from fossil-based resources, while maintaining the same high-quality performance parameters of traditional LYCRA® fiber.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005020/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The LYCRA Company signs an agreement with Qore® LLC to enable large-scale production of bio-derived spandex. Pictured – Julien Born, CEO of The LYCRA Company (left), and Jon Veldhouse, CEO of Qore® LLC (right), at The LYCRA Company’s headquarters in Wilmington, DE, USA. (Photo: Business Wire)

QIRA® will be produced at Cargill’s biotechnology campus and corn refining operation in Eddyville, Iowa. The facility, which is currently being built, will commence operations in 2024. The first renewable LYCRA® fiber made with QIRA® will be produced at The LYCRA Company’s Tuas, Singapore manufacturing site in 2024. The LYCRA Company is currently seeking commitments with brand and retail customers who are pursuing bio-derived solutions for their apparel.

“As part of our sustainability goals, we are committed to delivering products that support a more circular economy while helping our apparel and personal care customers reduce their footprint,” said Julien Born, CEO of The LYCRA Company. “We are especially pleased to collaborate with Qore®, a company that shares our vision for innovative, sustainable solutions. Their expertise in operating fermentation processes and understanding of the chemical value chains makes them the ideal partner to help develop a bio-derived LYCRA® fiber at commercial scale.”

“We are proud to partner with The LYCRA Company on bringing this sustainable material solution to the market. This collaboration demonstrates that QIRA® directly replaces conventional BDO and thus significantly improves the fiber’s sustainability profile,” said Jon Veldhouse, CEO of Qore®. “QIRA® is an innovative platform chemical that can be used in various applications across industries.”

The first generation of renewable LYCRA® fiber made with QIRA® will use feedstock from field corn grown by Iowa farmers and will enable a significant reduction in CO2 footprint. In addition to replacing a finite resource with an annually renewable one, another benefit for mills, brands and retailers is that there is no change in fiber performance, eliminating the need for any re-engineering of fabrics, patterns, or processes. Equivalent performance was demonstrated in 2014 when the world’s first bio-derived spandex was launched under the LYCRA® brand. The LYCRA Company has since been granted a patent for the process used to make renewable elastane from bio-derived BDO.

For additional information on renewable LYCRA® fiber, The LYCRA Company and Qore® invite interested parties to contact The LYCRA Company sales representatives.

*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll US Consulting, Inc.

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com.

LYCRA® is a trademark of The LYCRA Company.

About Qore® LLC

Formed through a joint venture by Cargill and HELM, Qore® will help leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 93% of greenhouse gas emissions when replacing today’s widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance.

For more information, visit www.myqira.com.

Qore® and QIRA® are trademarks of Qore® LLC.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Karie J. Ford karie.j.ford@Lycra.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Enters into Antibody Agreement with ADC Therapeutics28.11.2022 15:47:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales. Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogen’s Project Integrum (also called RenMiceTM HiTS

Medimaps Group Appoints Meinhard F. Schmidt as Board Chairman; Adds Anne Le Grand and Five Additional Board Members28.11.2022 15:15:00 CET | Press release

Medimaps Group (www.medimapsgroup.com), a Swiss/Global med-tech company specializing in image processing software for assessing bone health, today announced new appointments to its Board of Directors, effective immediately. Meinhard F. Schmidt, an international MedTech/BioTech and Digital Health executive with 25+ years of experience, has been named Board Chairman; and Anne Le Grand,an accomplished healthcare executive and consultant with 30+ years in the global healthcare technology industry, has joined as an independent board member. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005146/en/ Medimaps Group Announces Board Members: Meinhard F. Schmidt as Board Chairman, and Anne Le Grand Plus Five Other Members and One Strategic Advisor. (Photo: Business Wire) Five additional board members and one board advisor have also been named, bolstering Medimaps investment and clinical policy expertise. Visit Medimaps website fo

Viz.ai Appoints Radiology Advisory Board to Advance Innovation28.11.2022 14:00:00 CET | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Radiology Advisory Board to assist Viz.ai in the development of strategy and products to support radiologists and patients. The Board consists of 14 leading healthcare experts with diverse experience and roles in radiology. “I am honored to co-chair the Radiology Advisory Board and excited about Viz.ai’s commitment to customers and patients to invest in innovation that increases access to life-saving therapies,” said Kevin Abrams, MD, medical director of neuroradiology and MRI and chief of radiology at Baptist Hospital in Miami. “I am looking forward to the rich dialogue to be discussed in our inaugural meeting, exploring future ideas.” “I’m looking forward to working with these esteemed board members to help shape Viz.ai’s Radiology Program through patient-centric vision, passion, and insights,” said Suzie Bash, MD, Co-Chair of the Viz.ai Radiology Advisory Board a

Viz.ai Launches AI-powered Viz™ Radiology Suite28.11.2022 14:00:00 CET | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the introduction of an AI-powered radiology suite, specifically designed to alert the radiologist in their workflow of suspected diseases, prioritize worklists, and connect care teams in real-time. The Viz™ Radiology Suite integrates into the picture archiving and communication systems (PACS) of healthcare organizations to securely facilitate access to imaging data across departments and streamline patient diagnosis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005172/en/ Screen shots of Viz Radiology Suite including worklist and PACS integration (Graphic: Business Wire) “With an increasing demand for imaging studies and a global shortage of radiologists, technologies that can be easily integrated into radiology workflows to enhance efficiency and streamline patient care are sorely needed,” said Allan Brook, M.D., FA

Wipro Launches AWS Skills Guild Program: Step Up28.11.2022 13:55:00 CET | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, announced the launch of its new Skills Guild with Amazon Web Services (AWS) at AWS re:Invent 2022. AWS Skills Guild is a comprehensive enablement program for large enterprises to build cloud skills through integrated delivery of AWS learning opportunities. Wipro Step Up will use the AWS Skills Guild framework to transform the way employees engage with clients on their AWS Cloud journeys. “As the world continues to evolve and cloud becomes the foundation for business success, we are doubling down on our strategic partnerships to advance our clients’ business goals and help them drive new competitive advantage in a rapidly changing world,” said Jason Eichenholz, Senior Vice President and Global Head of Ecosystems and Partnerships, Wipro Limited. “Our Skills Guild builds on our existing cloud capabilities and deepens our AWS competencies to help clients drive accelerated ROI from AWS

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom